These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22547083)

  • 1. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3.
    Subramanian M; Agrawal V; Sandee D; Tam HK; Miller WL; Tracy TS
    Pharmacogenet Genomics; 2012 Aug; 22(8):590-7. PubMed ID: 22547083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
    Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
    Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19.
    Agrawal V; Huang N; Miller WL
    Pharmacogenet Genomics; 2008 Jul; 18(7):569-76. PubMed ID: 18551037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
    Agrawal V; Choi JH; Giacomini KM; Miller WL
    Pharmacogenet Genomics; 2010 Oct; 20(10):611-8. PubMed ID: 20697309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of POR mutations and polymorphisms.
    Miller WL; Agrawal V; Sandee D; Tee MK; Huang N; Choi JH; Morrissey K; Giacomini KM
    Mol Cell Endocrinol; 2011 Apr; 336(1-2):174-9. PubMed ID: 21070833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
    Velazquez MNR; Parween S; Udhane SS; Pandey AV
    Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
    Flück CE; Nicolo C; Pandey AV
    Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
    Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
    Locuson CW; Wienkers LC; Jones JP; Tracy TS
    Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus
    Gao Y; Ma J
    Expert Opin Drug Metab Toxicol; 2022; 18(7-8):529-535. PubMed ID: 35946839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
    Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency.
    Tomalik-Scharte D; Maiter D; Kirchheiner J; Ivison HE; Fuhr U; Arlt W
    Eur J Endocrinol; 2010 Dec; 163(6):919-24. PubMed ID: 20844025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.
    Chen X; Pan LQ; Naranmandura H; Zeng S; Chen SQ
    PLoS One; 2012; 7(6):e38495. PubMed ID: 22719896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency.
    Gomes LG; Huang N; Agrawal V; Mendonça BB; Bachega TA; Miller WL
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2913-6. PubMed ID: 18397975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
    Miller WL
    Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
    Crespi CL; Miller VP
    Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
    Subramanian M; Low M; Locuson CW; Tracy TS
    Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy.
    Gong L; Zhang CM; Lv JF; Zhou HH; Fan L
    Pharmacogenet Genomics; 2017 Sep; 27(9):337-346. PubMed ID: 28731962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase.
    Flück CE; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):64-70. PubMed ID: 27032764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electron transfer by human wild-type and A287P mutant P450 oxidoreductase assessed by transient kinetics: functional basis of P450 oxidoreductase deficiency.
    Jin Y; Chen M; Penning TM; Miller WL
    Biochem J; 2015 May; 468(1):25-31. PubMed ID: 25728647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.